Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach